Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Frontier Biotech's HIV Drug Approved, First China-Developed HIV Treatment

publication date: Jun 6, 2018

Nanjing Frontier Biotech received CFDA approval for China use of albuvirtide, its novel long-acting treatment for HIV. Albuvirtide, a once-weekly injectable product, is the first China-developed HIV treatment to be approved for commercialization and also the first long-acting HIV treatment approved anywhere in the world. According to Frontier, albuvirtide has a novel mechanism of action that makes the molecule effective against common strains of HIV-1, including drug-resistant varieties. It believes the drug offers low frequency of dosing, high barriers to resistance and fewer side effects. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital